Noveris Health Sciences Inc. (MYCOF)

Profile

https://mydecine.com

Noveris Health Sciences Inc. is a publicly traded, pre-revenue biopharmaceutical company engaged in the research, development, and commercialization of psychedelic-inspired medications to treat mental health and neurological conditions. The company focuses on developing second-generation compounds derived from psilocybin and MDMA for treating conditions including nicotine addiction, post-traumatic stress disorder, depression, anxiety, pain, and neurodegenerative disorders. Noveris's lead product candidates include MYCO-005, MYCO-006, and MYCO-007, which represent patent-pending MDMA and psilocybin analogs. The company leverages modern drug chemistry and artificial intelligence to create safer, more effective, and more accessible therapeutic options compared to traditional treatments. Noveris operates through a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery and research and development on empathogenic and entactogenic compounds. The company began operations in North America and Europe in early 2020 and is headquartered in Vancouver, Canada, having been incorporated in 2013.